当前位置: 首页 >> 检索结果
162. Recombinant herpes zoster vaccine in patients with autoimmune rheumatic diseases in Brazil: a double-blind, randomised, placebo-controlled, phase 4, non-inferiority study.
作者: Nadia E Aikawa.;Ana C Medeiros-Ribeiro.;Sandra G Pasoto.;Leonard V K Kupa.;Luciana P C Seguro.;Ana P Luppino-Assad.;Eduardo F Borba.;Carla G S Saad.;Emily F N Yuki.;Danieli C O Andrade.;Andrea Y Shimabuco.;Karina R Bonfiglioli.;Diogo S Domiciano.;Julio C B Moares.;Samuel K Shinjo.;Percival D Sampaio-Barros.;Henrique A M Giardini.;João C S de Oliveira.;Isabele P B Antonelli.;Renata L P Mello.;Thais B Gorayeb.;Lucas G N Farias.;Andrea A Negrini.;Fernanda G G Chaer.;Ana C S L Praxedes.;Marta H Lopes.;Clovis A Silva.;Eloisa Bonfa.
来源: Lancet Rheumatol. 2026年
Patients with autoimmune rheumatic diseases are at high risk of developing herpes zoster due to immunosuppressive treatment. We evaluated the effect of a recombinant zoster vaccine in patients with autoimmune rheumatic diseases compared with placebo and in healthy controls.
163. Effectiveness of denosumab, teriparatide and romosozumab for glucocorticoid-induced osteoporosis: a propensity score-matched cohort study.
作者: Toshitaka Yukishima.;Tomonori Kobayakawa.;Yuji Hirano.;Yasuhide Kanayama.;Rui Niimi.;Yuki Etani.;Takaaki Noguchi.;Kumiko Shimoyama.;Yuichiro Maekawa.;Ken Nakata.;Seiji Okada.;Kosuke Ebina.
来源: Rheumatology (Oxford). 2026年65卷3期
To investigate the effectiveness of denosumab (DMAb), teriparatide (TPTD) and romosozumab (ROMO) in patients with glucocorticoid-induced osteoporosis (GIOP).
164. Glucocorticoid tapering strategies in polymyalgia rheumatica: a systematic literature review.
作者: Noortje E S E P Kooijman.;Bart J F van den Bemt.;Lenny van Bon.;Elisabeth Brouwer.;Aatke van der Maas.;Maike H M Wientjes.
来源: Rheumatology (Oxford). 2026年65卷2期
Glucocorticoids (GCs) are the cornerstone of polymyalgia rheumatica (PMR) treatment, but the optimal tapering strategy remains unclear. This systematic review aimed to explore the impact of published GC tapering strategies on remission, flare rates, GC discontinuation, cumulative GC doses and patient-reported outcomes (PROs).
165. Vascular events in autoantibody-defined clusters of SLE: a 12-year prospective cohort study.
作者: Sara Ferrigno.;Elizabeth V Arkema.;Iva Gunnarsson.;Aleksandra Antovic.;Agneta Zickert.;Lina-Marcela Diaz-Gallo.;Elisabet Svenungsson.
来源: Rheumatology (Oxford). 2026年65卷2期
We recently identified four SLE clusters based on 13 autoantibodies used in clinical practice. In this prospective cohort study, we investigate the incidence of major cardiovascular events (MACE) and venous thromboembolism (VTE) in SLE patients stratified by clusters. Clusters were compared with each other and to matched controls.
166. Digital interactions with the pharmaceutical industry: a qualitative focus group study on the perspectives of rheumatology care providers in Germany.
作者: Susann May.;Amina Jeleskovic-Öztürk.;Hannah Meisberger.;Finnja Stangel.;Katharina Boy.;Niklas Ohm.;Greta Nordmann.;Robert Darkow.;Johannes Knitza.;Felix Muehlensiepen.
来源: BMC Rheumatol. 2026年10卷1期
Digitalization is reshaping healthcare delivery, including how physicians and the pharmaceutical industry interact. Rheumatology care is a particularly dynamic field, where digital technologies are increasingly integrated into both clinical care and pharmaceutical engagement. Despite growing digital collaboration, little is known about healthcare professionals’ perspectives on these developments.
167. Preferences, experiences and needs regarding tobacco cessation expressed among patients with rheumatoid arthritis: a qualitative study.
作者: Maria A Lopez-Olivo.;Sheneze Madramootoo.;Johncy J Kachira.;Kaleb Michaud.;Rebecca Schumacher.;Paul Cinciripini.;Maria E Suarez-Almazor.
来源: BMC Rheumatol. 2026年10卷1期
Smoking presents significant challenges for individuals with rheumatoid arthritis (RA) yet understanding of their smoking habits and perceptions remains limited. This study explores preferences regarding tobacco cessation strategies, barriers to success in cessation, and perceived needs in this population.
172. Peripheral manifestations in spondyloarthritis: a systematic literature review on their assessment and the effect of biological/targeted synthetic DMARDs.
作者: Casper Webers.;Augusta Ortolan.;Elena Nikiphorou.;Alexandre Sepriano.;Louise Falzon.;Clementina López-Medina.;Dafne Capelusnik.;Désirée van der Heijde.;Anna Moltó.;Sofia Ramiro.
来源: Rheumatology (Oxford). 2026年65卷2期
Peripheral manifestations (peripheral arthritis/enthesitis/dactylitis) are frequent in axial spondyloarthritis (axSpA) yet, understudied. We (i) evaluated the assessment/reporting of peripheral manifestations in trials of biological or targeted synthetic DMARDs (b/tsDMARDs) for axSpA and peripheral SpA (pSpA), and (ii) synthesized the efficacy of b/tsDMARDs on these manifestations.
174. Worldwide trends in hyperuricaemia from 2000 to 2023: a systematic review and modelling analysis.
作者: Madeleine Ngandeu-Singwe.;Jan René Nkeck.;Aghiles Hamroun.;Francky Teddy Endomba.;Caroline Ngoufack-Tientcheu.;Aude Laetitia Ndoadoumgue.;Baudelaire Talongong Fojo.;Anderson T Ngouo.;Dahlia Noelle Tounouga.;Jeriel Pascal Nkeck.;Emilie Letticia Youda.;Estelle Amandine Well.;Jean Joel Bigna.
来源: Lancet Rheumatol. 2026年
Hyperuricaemia is not currently included in major global health surveillance frameworks, including the Global Burden of Diseases, Injuries, and Risk Factors Study, despite its well established clinical associations with non-communicable diseases. The absence of harmonised, comparable sex-specific prevalence estimates of hyperuricaemia across countries has limited its visibility in public health planning and prevention strategies. We aimed to provide the first standardised, sex-specific, global, regional, and national estimates of hyperuricaemia prevalence and cases from 2000 to 2023.
177. Patient profiles and early response in patients with systemic lupus erythematosus initiating anifrolumab: interim analysis from the ongoing multicentre observational REVEAL study.
作者: Chiara Tani.;Chiara Cardelli.;Luca Moroni.;Margherita Zen.;Francesca Bottazzi.;Micaela Fredi.;Alessandra Bortoluzzi.;Matteo Piga.;Flavia Riccio.;Fulvia Ceccarelli.;Ginevra De Marchi.;Lucia Manfredi.;Rita Mulè.;Edoardo Biancalana.;Mariele Gatto.;Laura Coladonato.;Paola Conigliaro.;Maria Gerosa.;Andrea Picchianti Diamanti.;Giuseppe Alvise Ramirez.;Filippo Vesentini.;Giovanni Zanframundo.;Chiara Orlandi.;Ettore Silvagni.;Elisabetta Chessa.;Marica Trevisani.;Miki Palmerini.;Pietro Francesco Gavino Pilo.;Sara Ferrigno.;Anna Chiara Di Lollo.;Silvia Noviello.;Alberto Lo Gullo.;Maria Ilenia De Andres.;Serena Guiducci.;Giacomo Emmi.;Federica Maiolini.;Rossella De Angelis.;Roberto Felice Caporali.;Florenzo Iannone.;Gianluca Moroncini.;Luca Quartuccio.;Fabrizio Conti.;Francesco Ciccia.;Marcello Govoni.;Franco Franceschini.;Lorenzo Cavagna.;Luca Iaccarino.;Lorenzo Dagna.;Marta Mosca.
来源: Lancet Rheumatol. 2026年8卷3期e181-e191页
Anifrolumab is a type I interferon receptor antagonist approved for the treatment of systemic lupus erythematosus (SLE). However, real-world evidence on its use, especially from large, unselected cohorts, is scarce. The ongoing REVEAL study is designed to collect real-world data on anifrolumab use. The data reported here are the pre-specified 6-month interim analysis, which aims to provide a phenotypic characterisation of a large real-world cohort of patients with SLE initiating anifrolumab, and to evaluate early treatment response in routine clinical practice.
179. NRAS and SREBF1 identified as mitophagy-associated risk genes for rheumatoid arthritis through interpretable machine learning and experimental validation studies.
作者: Hongman Li.;Peng Liu.;Xiao Han.;Shengyong Si.;ZhiJing Li.;Chun Zhao.;Xue Zhao.;Xue Zhou.;Mengdie Liu.
来源: BMC Rheumatol. 2026年10卷1期
Mitophagy has been implicated in the pathogenesis of rheumatoid arthritis (RA), particularly in fibroblast-like synoviocytes (FLSs), yet its regulatory landscape and diagnostic relevance remain incompletely understood. This study aimed to identify mitophagy-associated genes (MRGs) in RA and to explore their potential diagnostic value using integrative bioinformatics and interpretable machine learning approaches.
|